Iovance Biotherapeutics Inc. (IOVA)
NASDAQ: IOVAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IOVA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.19B
- EPS (TTM)
- -$0.49
- Dividend yield
- None
- 52-week range
- 2.08 – 15.37
- Day range
- 6.77 – 7.40
- Volume / Avg
- 13.73M / 14.91M
- Beta
- —
- Shares outstanding
- 462.66M
52-week range
IOVA stock today
Shares of Iovance Biotherapeutics (IOVA) finished lower on Nov 20 at $6.90, a drop of 5.61% or $0.41 per share, versus the S&P 500's 3.70% decline. Shares are 55.1% below their 52-week high of $15.37, set on Oct 21, 2026 and 231.7% above the 52-week low of $2.08, in the middle of the past year's range. IOVA is up 152.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 208.0%.
Iovance Biotherapeutics has posted a net loss over the last twelve months (EPS of -$0.49), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Iovance Biotherapeutics
Company profileIovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Frederick G. Vogt Esq., J.D., Ph.D.
- Headquarters
- Philadelphia, PA
- Employees
- 975
- Website
- iovance.com
Financial highlights
Full financialsIn fiscal 2025, Iovance Biotherapeutics generated $263.5 million in revenue, up 60.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Iovance Biotherapeutics reported a net loss of $391.0 million, compared with a loss of $372.2 million a year earlier. Gross margin was 34.3% (down from 43.2%) and operating margin -153.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $263.50M | $164.07M | $1.19M | — | — |
| Growth | +60.60% | +13698.99% | — | — | — |
| Net income | $-390.98M | $-372.18M | $-444.04M | $-395.89M | $-342.25M |
| EPS (diluted) | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 |
Analyst forecast
ForecastConsensus (9 analysts)
buy
Avg. price target
$14.50+110.14%
- Strong buy 2
- Buy 5
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.05 vs $-0.09
- Surprise
- +44.44%
IOVA news
All IOVA news- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D CostsNasdaqIOVA, MRK, TGTX, AMRX
- Iovance Biotherapeutics GAAP EPS of -$0.05 beats by $0.04, revenue of $121.47M beats by $5.9MSeeking Alpha
- Iovance Biotherapeutics Q3 2026 Earnings PreviewSeeking Alpha
- AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance RaisedNasdaqAMRX, TGTX, IOVA, IBRX
- NVO Q3 Earnings Beat Estimates on Wegovy Pill Growth, Outlook RaisedNasdaqNVO, TGTX, IOVA, IBRX
- Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone RevenuesNasdaqRXRX, SNY, IOVA, AMRX
- Zoetis Gears Up to Report Q3 Earnings: Here's What to ExpectNasdaqZTS, TGTX, IOVA, JSPR
Iovance Biotherapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DNLIDenali Therapeutics Inc. | 18.45 | +1.37% | $2.96B | vs IOVA |
| VCELVericel Corporation | 57.52 | -1.27% | $2.94B | vs IOVA |
| ADMAADMA Biologics Inc | 13.17 | -1.27% | $2.92B | vs IOVA |
| RLAYRelay Therapeutics Inc. | 16.12 | +1.32% | $3.56B | vs IOVA |
| TARSTarsus Pharmaceuticals Inc. | 73.01 | -6.00% | $3.60B | vs IOVA |
| CRSPCRISPR Therapeutics AG | 39.10 | +0.44% | $3.79B | vs IOVA |
| BEAMBeam Therapeutics Inc. | 20.90 | -0.19% | $2.16B | vs IOVA |
| ADPTAdaptive Biotechnologies Corporation | 27.93 | -0.43% | $4.52B | vs IOVA |
Indexes, lists and sector
Iovance Biotherapeutics stock FAQ
What is Iovance Biotherapeutics's stock price today?
IOVA last traded at $6.90 as of Nov 20, 4:00 PM EST, down 5.61% on the day. Prices are delayed at least 15 minutes.
Does Iovance Biotherapeutics pay a dividend?
No. Iovance Biotherapeutics does not currently pay a regular cash dividend.
Who is Iovance Biotherapeutics's CEO?
Dr. Frederick G. Vogt Esq., J.D., Ph.D. is the chief executive officer of Iovance Biotherapeutics Inc., which has about 975 employees.
Has IOVA ever split its stock?
Yes. The most recent IOVA stock split was a 1-for-100 split on Sep 26, 2013.
What is the IOVA 52-week high?
The 52-week high for IOVA is $15.37 and the 52-week low is $2.08. The stock is currently 55.1% below its high.